Juno Therapeutics, Inc. announced encouraging preliminary clinical data from a phase I study (TRANSCEND) on its lead pipeline candidate, JCAR017, for the treatment of patients with relapsed or refractory (r/r) aggressive non-Hodgkin lymphoma (NHL). Results were presented at the 58th American Society of Hematology (ASH) Annual Meeting.
Juno’s shares lost 18.3% in the past one month, comparing unfavorably with an increase of 3% for the Zacks classified Medical-Biomed/Genetic industry.
Note that JCAR017 enjoys orphan drug designation for the treatment of acute lymphoblastic leukemia (ALL), diffuse large B cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL).
The multi-center TRANSCEND trial demonstrated 60% complete response in patients with relapsed or refractory aggressive cd19+ NHL. The company believes that the favorable side effect profile and persistence of CAR T cells observed in the TRANSCEND study will allow it to evaluate higher doses of the drug. Moreover, the candidate showed potential to be used for combination therapy to improve long-term outcomes. The company continues to enroll patients at dose levels 1 and 2 of the trial.
Juno intends to initiate a pivotal trial in the U.S. on patients with r/r DLBCL in 2017. JCAR017 is also being studied in a phase II study in children with r/r ALL. The company expects to obtain an FDA approval for the candidate for the treatment of NHL as early as 2018.
We note that Juno entered into an agreement with Celgene Corporation in Jun 2015 for the global development and commercialization of immunotherapies with initial focus on chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies. In Apr 2016, Celgene exercised its option to develop and commercialize Juno’s CD19 program outside North. The deal is a major positive for Juno, as it provides the company not only funds, but also a strong partner in Celgene.
Zacks Rank & Key Picks
Juno currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the health care sector include Heska Corp. and Cambrex Corp. . Each of these stocks sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Heska’s earnings estimates increased from $1.13 to $1.35 for 2016 and from $1.38 to $1.53 for 2017 over the last 60 days. The company posted a positive earnings surprise in all of the four trailing quarters with an average beat of 301.64%. Its share price has increased 68.7% year to date.
Cambrex’s earnings estimates increased from $2.46 to $2.55 for 2016 and from $2.91 to $3.06 for 2017 over the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 19.78%. Its share price has increased 7.7% year to date.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
Image: Bigstock
Juno Reports Positive Phase I Study Data on Lymphoma Drug
Juno Therapeutics, Inc. announced encouraging preliminary clinical data from a phase I study (TRANSCEND) on its lead pipeline candidate, JCAR017, for the treatment of patients with relapsed or refractory (r/r) aggressive non-Hodgkin lymphoma (NHL). Results were presented at the 58th American Society of Hematology (ASH) Annual Meeting.
Juno’s shares lost 18.3% in the past one month, comparing unfavorably with an increase of 3% for the Zacks classified Medical-Biomed/Genetic industry.
Note that JCAR017 enjoys orphan drug designation for the treatment of acute lymphoblastic leukemia (ALL), diffuse large B cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL).
The multi-center TRANSCEND trial demonstrated 60% complete response in patients with relapsed or refractory aggressive cd19+ NHL. The company believes that the favorable side effect profile and persistence of CAR T cells observed in the TRANSCEND study will allow it to evaluate higher doses of the drug. Moreover, the candidate showed potential to be used for combination therapy to improve long-term outcomes. The company continues to enroll patients at dose levels 1 and 2 of the trial.
Juno intends to initiate a pivotal trial in the U.S. on patients with r/r DLBCL in 2017. JCAR017 is also being studied in a phase II study in children with r/r ALL. The company expects to obtain an FDA approval for the candidate for the treatment of NHL as early as 2018.
We note that Juno entered into an agreement with Celgene Corporation in Jun 2015 for the global development and commercialization of immunotherapies with initial focus on chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies. In Apr 2016, Celgene exercised its option to develop and commercialize Juno’s CD19 program outside North. The deal is a major positive for Juno, as it provides the company not only funds, but also a strong partner in Celgene.
JUNO THERAPEUTC Price
JUNO THERAPEUTC Price | JUNO THERAPEUTC Quote
Zacks Rank & Key Picks
Juno currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the health care sector include Heska Corp. and Cambrex Corp. . Each of these stocks sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Heska’s earnings estimates increased from $1.13 to $1.35 for 2016 and from $1.38 to $1.53 for 2017 over the last 60 days. The company posted a positive earnings surprise in all of the four trailing quarters with an average beat of 301.64%. Its share price has increased 68.7% year to date.
Cambrex’s earnings estimates increased from $2.46 to $2.55 for 2016 and from $2.91 to $3.06 for 2017 over the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 19.78%. Its share price has increased 7.7% year to date.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>